


Supplemental Figure 1. Tumor-specific antibodies in LLC or TC-1 model and tumor-infiltrating immune cells of LLC tumor-bearing mice.

A) LLC tumor cells (1.0×10^6) or TC-1 tumor cells (1.0×10^5) were injected s.c. into C57Bl/6 mice. Sera were collected at day 28. LLC or TC-1 tumor cells were incubated with 0.3% serum and analyzed via flow cytometry as described in Fig. 1A. Results were independently evaluated for each mouse, and the data represent the means with SD of five mice per group. B) Mice were treated as described in Fig. 2. LLC tumors were removed at day 28 and analyzed via flow cytometry as described in Fig. 4. Results were independently evaluated for each mouse, and the data represent the means with SD of 6–10 mice per group from two independent experiments. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ compared with naïve or WT mice.



Supplemental Figure 2. Gene expression at tumor sites in LLC model or spleen from tumor-free mice.

A) LLC tumors were removed at day 28 and analyzed for the expression of the indicated mRNAs by qPCR. Data represent the means with SD of 6–12 mice per group from two independent experiments. B) Spleen cells were removed from tumor-free WT or FcγRIIB KO mice and analyzed for the expression of the indicated mRNAs by qPCR. Data represent the means with SD of six mice per group. ** P < 0.01 and *** P < 0.001 compared with naïve or WT mice.

Supplemental Table 1. Summary of tumor-specific immune response and tumor growth in several tumor cell lines.

Tumor cells	Antitumor Ab production	Tumor growth inhibition	Antitumor immunity	Inflammation in the tumor
E. G7	+	+	+	+
LLC	+	+	ND	+
TC-1	+	+	+	+
B16	+	-	ND	ND

NOTE: +; significant difference, ND; not determined.